Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions.
Bishop CA, Newbould RD, Lee JS, Honeyfield L, Quest R, Colasanti A, Ali R, Mattoscio M, Cortese A, Nicholas R, Matthews PM, Muraro PA, Waldman AD. Bishop CA, et al. Among authors: ali r. Neuroimage Clin. 2016 Nov 9;13:9-15. doi: 10.1016/j.nicl.2016.11.005. eCollection 2017. Neuroimage Clin. 2016. PMID: 27896065 Free PMC article.
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. Uccelli A, et al. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z. Trials. 2019. PMID: 31072380 Free PMC article.
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS; MESEMS investigators. Uccelli A, et al. Among authors: ali r. Lancet Neurol. 2021 Nov;20(11):917-929. doi: 10.1016/S1474-4422(21)00301-X. Lancet Neurol. 2021. PMID: 34687636 Clinical Trial.
Soluble CD27 is an intrathecal biomarker of T-cell-mediated lesion activity in multiple sclerosis.
Cencioni MT, Magliozzi R, Palmisano I, Suwan K, Mensi A, Fuentes-Font L, Villar LM, Fernández-Velasco JI, Migallón NV, Costa-Frossard L, Monreal E, Ali R, Romozzi M, Mazarakis N, Reynolds R, Nicholas R, Muraro PA. Cencioni MT, et al. Among authors: ali r. J Neuroinflammation. 2024 Apr 12;21(1):91. doi: 10.1186/s12974-024-03077-9. J Neuroinflammation. 2024. PMID: 38609999 Free PMC article.
Does natalizumab therapy worsen neuromyelitis optica?
Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild M. Jacob A, et al. Among authors: ali r. Neurology. 2012 Sep 4;79(10):1065-6. doi: 10.1212/WNL.0b013e31826845fe. Epub 2012 Aug 22. Neurology. 2012. PMID: 22914835 No abstract available.
3,255 results